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Background: Marine derived oils are rich in long-chain polyunsaturated omega-3 fatty acids, in particular eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), which have long been associated with health promoting effects such as
reduced plasma lipid levels and anti-inflammatory effects. Krill oil (KO) is a novel marine oil on the market and is also
rich in EPA and DHA, but the fatty acids are incorporated mainly into phospholipids (PLs) rather than triacylglycerols
(TAG). This study compares the effects of fish oil (FO) and KO on gene regulation that influences plasma and liver lipids
in a high fat diet mouse model.
Methods: Male C57BL/6J mice were fed either a high-fat diet (HF) containing 24% (wt/wt) fat (21.3% lard and 2.3% soy
oil), or the HF diet supplemented with FO (15.7% lard, 2.3% soy oil and 5.8% FO) or KO (15.6% lard, 2.3% soy oil and
5.7% KO) for 6 weeks. Total levels of cholesterol, TAG, PLs, and fatty acid composition were measured in plasma and
liver. Gene regulation was investigated using quantitative PCR in liver and intestinal epithelium.
Results: Plasma cholesterol (esterified and unesterified), TAG and PLs were significantly decreased with FO. Analysis
of the plasma lipoprotein particles indicated that the lipid lowering effect by FO is at least in part due to decreased
very low density lipoprotein (VLDL) content in plasma with subsequent liver lipid accumulation. KO lowered plasma
non-esterified fatty acids (NEFA) with a minor effect on fatty acid accumulation in the liver. In spite of a lower omega-3
fatty acid content in the KO supplemented diet, plasma and liver PLs omega-3 levels were similar in the two groups,
indicating a higher bioavailability of omega-3 fatty acids from KO. KO more efficiently decreased arachidonic acid and its
elongation/desaturation products in plasma and liver. FO mainly increased the expression of several genes involved in
fatty acid metabolism, while KO specifically decreased the expression of genes involved in the early steps of isoprenoid/
cholesterol and lipid synthesis.
Conclusions: The data show that both FO and KO promote lowering of plasma lipids and regulate lipid homeostasis,
but with different efficiency and partially via different mechanisms.
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Omega-3 polyunsaturated fatty acids (PUFAs) such as
eiocosapentaenoic acid (EPA) and docosapentaenoic acid
(DHA) are well known bioactive dietary compounds that
are found particularly in marine-derived food sources
such as e.g. fatty fish, seaweed, shellfish, microalgae and
krill. Since 1970, regular consumption of fish (preferably
fatty fish) has been stated to have several positive effects
on cardiovascular health [1-5]. The American Heart
Association dietary guidelines for healthy individuals
proposes consumption of at least two servings of fish
per week which should yield an intake of approximately
400-500 mg EPA and DHA, and they recommend an
even higher intake of omega-3 fatty acids to patients
with documented coronary heart disease [6,7]. However,
in large parts of the world the consumption of fish is
considered to be inadequate and fish oil (FO) from an-
chovy, sprat, herring and salmon as a source of DHA
and EPA has become widely used as a dietary supple-
ment. The reported health benefits of FO have however
led to an increased demand that may endanger natural
resources of fish, and krill oil (KO) has recently emerged
on the market as an alternative source of omega-3 PUFAs.
Most FO on the market today have their omega-3 PUFAs
incorporated into (triacylglycerols) TAG or in ethyl esters.
However in KO are the majority of these omega-3 PUFAs
esterified in phospholipids (PLs) [8-11]. KO has been
stated to be a safe source of EPA and DHA that like other
marine-based oils is able to efficiently raise the plasma
levels of EPA and DHA [12-16]. However, the structural
differences in the PUFA-rich lipid molecules may affect
the distribution in cellular lipid fractions and tissue uptake
and thereby promote different regulatory effects on lipid
homeostasis [17]. KO also contains astaxanthin, which
due to its anti-oxidative effect, might enhance the stability
of the omega-3 PUFAs in the oil and thereby preserve
them from lipid oxidation [10].
Intake of EPA and DHA has been shown to improve
cardiovascular health by regulating lipid and glucose me-
tabolism by acting as ligands for several nuclear tran-
scription factors (e.g. peroxisome proliferator-activated
receptors (PPARs) -α, -β/δ, and -γ and sterol regulatory
element-binding protein 1 (SREBP-1)) [18-20]. EPA and
DHA also have anti-inflammatory effects due to their
conversion to less inflammatory signaling molecules at
the expense of production of pro-inflammatory mole-
cules from arachidonic acid (for reviews see [21,22]).
The liver is a central metabolic organ that regulates
both circulating blood lipids and glucose levels by catab-
olism as well as synthesis of lipids and carbohydrates.
Marine-derived omega-3 PUFAs have previously been
shown to modulate the gene transcription profile in liver
to enhance lipid degradation and decrease VLDL secre-
tion (for review, see [23]). Recently, also KO was shownto modulate the transcriptional profile in mouse and
rat liver and to affect plasma and liver lipids in mice
[24-28].
Gene expression is regulated in the intestine in re-
sponse to different metabolic conditions in order to cope
with changes in nutrient load and content, to signal sati-
ety and other stimuli to the rest of the body and to keep
the intestinal defense barrier against pathogens intact. In
addition, the intestine contributes to the plasma lipopro-
tein profile by absorbing lipids for chylomicron synthesis
and being responsible for a significant part of the HDL
production in the body [29,30]. To the best of our know-
ledge, so far no study has addressed the effects of KO on
regulation of gene expression in the small intestine,
although KO was recently shown to attenuate inflamma-
tion and oxidative stress in colon in an experimental rat
model of ulcerative colitis [31].
The aim of this study was to compare the effects of
two of the major sources of omega-3 supplements on
the market today, FO and KO, when supplemented to a
Western-like high-fat diet.
Equal amount of FO and KO (6% by weight) were
added to a high fat diet, and the effects on plasma and
liver lipids and gene regulation in liver and intestine
were measured. In spite of the markedly lower omega-3
PUFA content in KO, both dietary supplementations
raised the content of omega-3 PUFAs in plasma as well
as in liver phospholipids to a similar extent. However,
FO more efficiently lowered plasma lipids and this
decrease was associated with accumulation of lipids in
liver. In contrast, KO was less efficient in lowering
plasma lipids with less, if any, sign of TAG accumulation
in the liver. These different effects by FO and KO can at
least in part be ascribed to differential regulation of gene
expression in liver and intestine and different effects on
VLDL secretion.
Methods
Animals and diets
Nine to ten week old male C57BL/6J mice were fed
either a high-fat diet (HF) containing 24% (wt/wt) fat
(21.3% lard and 2.3% soy oil, n = 9), or the HF diet
supplemented with FO (EPAX 6000 TG®, a generous gift
of Epax A/S, Ålesund, Norway) (15.7% lard, 2.3% soy oil
and 5.8% FO, n = 6) or the HF diet supplemented with
KO (Superba™, a generous gift of Aker BioMarine, Oslo,
Norway) (15.7% lard, 2.3% soy oil and 5.7% KO, n = 6)
and water ad libitum for 6 weeks. Diets were packaged
in airtight bags and freeze stored until use to prevent
lipid oxidation. Mice were housed in groups of three per
cage at a constant temperature of 22 ± 2°C and a light/
dark cycle of 12/12 h. Body weights of the animals were
measured approximately every seventh day and food
intake was measured three times in the beginning of the
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fasted overnight, anesthetized with 2% isoflurane (Scher-
ing-Plough, Kent, UK) and blood was collected by heart
puncture. The blood was centrifuged and EDTA-plasma
was frozen until further analysis. Livers were collected
and the intestines were removed, rinsed with ice-cold phos-
phate buffered saline, cut into four segments of equal
length that were further cut open and the epithelial cell
layers were scraped off to separate the epithelial cells from
the smooth muscle. All tissue samples were immediately
frozen in liquid nitrogen and stored at -80°C until further
analysis. The animal experiments were carried out with eth-
ical permission obtained from the Norwegian State Board
for Biological Experiments and followed the Norwegian
Research Councils ethical guidelines.
RNA isolation and cDNA synthesis
Total RNA from the intestinal epithelium and liver tissues
was purified using the MagMax total RNA isolation sys-
tem (Applied Biosystems, Carlsbad, CA, USA) after tissue
homogenization. The quantity of the RNA was measured
spectrophotometrically using a NanoDrop 1000 (Nano-
Drop Products, Wilmington, DE, USA) and the quality of
the RNA was analyzed using the Experion Automated
Electrophoresis System (Bio-Rad Laboratories, Hercules,
CA, USA). The quality limit for further use of RNA was
set to a R/Q value of ≥7 (out of 10). cDNA was synthe-
sized with 500 ng RNA per reaction, using High Capacity
RNA-to cDNA Mastermix (Applied Biosystems).
Real-time PCR
Two types of TaqMan® Low Density Arrays in 96-well
formats (format 96b, Applied Biosystems) were custom
made to investigate the expression of genes related to
peroxisomal and mitochondrial metabolic pathways, re-
spectively (see Additional file 1 for gene lists). The plates
were run at the Bioinformatics and Expression Analysis
core facility (BEA) at Karolinska Institutet and the run
data were analyzed by RQ Manager (Applied Biosys-
tems). Gene expression was calculated using the 2^-ΔΔCt
method according to Livak et al. [32], using 18S as refer-
ence gene and one individual sample in the high fat
group as a calibrator (n = 4 per group). Some additional
genes of interest (not being on the TLDA-plates) were
analyzed in individual samples from liver and intestine
(HF n = 6, FO n = 5, KO n = 6) using TaqMan or SYBR
Green gene expression assays (for primers and additional
TaqMan expression assays, see Additional file 1). SYBR
Green primers were used at concentrations ranging from
100 to 200 nM and run with the Power SYBR Green
Master Mix (Applied Biosystems). Again, gene expres-
sion data were calculated using the 2^-ΔΔCt method
(due to known efficiency of the primers used in the
SYBR Green assay), however, the average Ct value ofthree different reference genes (18S, Hprt and Ppia) was
used as control values and one individual sample in the
high fat group as a calibrator.
Lipid analysis
Liver lipids were extracted according to Bligh and Dyer
[33], solvents were evaporated under nitrogen and the
samples were re-dissolved in isopropanol before analysis.
Lipids from liver extracts or plasma were then measured
enzymatically on a Hitachi 917 system (Roche Diagnos-
tics, Mannheim, Germany) using kits for analyzing total
TAG (GPO-PAP kit, Roche Diagnostics), cholesterol
(CHOD-PAP kit, Roche Diagnostics), total PLs (bioMér-
ieux SA, Marcy l'Etoile, France) and NEFA (FS kit,
DiaSyS, Holzheim, Germany). Aliquots of extracted liver
lipids were separated by thin layer chromatography
using silica gel plates (Merck, Darmstadt, Germany) and
hexane:diethylether (1:1) as the liquid phase. The abso-
lute levels of fatty acids of the diets, plasma and the
TAG and PL fractions from livers were analyzed using
gas chromatography as described previously by Grimstad
et al. [31]. Lipoproteins were analyzed by size exclusion
chromatography of plasma samples from individual mice
(five mice in each group) according to Parini et al. [34].
Hepatic enzyme activities
The liver tissue samples were homogenized and post-
nuclear fractions were prepared as previously described
[35]. Carnitine palmitoyltransferase 1 (CPT-I) activity
was measured in the absence and presence of malonyl-
CoA (15 μM) essentially as described by Bremer [36].
Peroxisomal acyl-CoA oxidase (ACOX) activity was de-
termined by the coupled assay described by Small et al.
[37] and fatty acid synthase (FAS) activity was measured
as described by Skorve et al. [38].
Statistics
Since normal distribution could not be assumed for the
number of animal used in this study, the Kruskal-Wallis
test was used for analysis of differences among the
groups. If significance was obtained (p < 0.05) with the
Kruskal-Wallis test, Dunn’s multiple comparison test
was performed on all combinations, i.e. FO vs. KO, FO
vs. high fat and KO vs. high fat. Significance indicated in
tables and figures is shown for the Kruskal-Wallis test
(as p-values in tables or as “K-W” in figures), and if
significance was obtained in the Kruskal-Wallis test, also
significance obtained by the post hoc test between the
individual groups is indicated. A trend of difference
between groups was set to 0.1 > p > 0.05 for the Kruskal-
Wallis test. All values are presented as median and
range. The statistics were calculated using GraphPad
Prism 5.0d.
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Diet composition
The three different diets were isocaloric high-fat diets
with 6% of the lard being exchanged for FO or KO.
Although both FO and KO are rich in omega-3 PUFAs,
there were differences in the fatty acid amount and com-
position between the two diets. The FO supplemented
diet contained approximately double the amount of
omega-3 PUFAs (about 3.7%, wt/wt) compared to the
KO supplemented diet (about 1.8%, wt/wt). Instead the
KO diet contained slightly more saturated (C14:0 and
C16:0) and monounsaturated fatty acids than the FO
diet (see Table 1 and Additional file 2).0 5 10 15 20 25 30 35 40 45
20
Days
Figure 1 Body weight gain. The mice were weighed weekly and
the figure shows body weights as median ± range of the animals in
the three groups from day 0 to the endpoint at 6 weeks of feeding the
different diets. Filled squares; HF (n = 9), open triangles; FO (n = 5), filled
triangles; KO (n = 6). K-W* = significance by Kruskal-Wallis, a = HF vs. FO,
c = FO vs. KO, * = p < 0.05 in Dunn post hoc test.Body weight gain and liver weight
Body weights of the mice were not significantly different
between the three groups at any of the time points ex-
cept for a drop in the FO group at day 37 for unknown
reasons (see Figure 1). Also the final weights of the
animals were not significantly different (Table 2). One
mouse in the FO group died early in the study, unlikely
due to the treatment, reducing the number to five in this
group. Food intake was only measured three times at the
beginning of the study to optimize the food supply in
order to minimize any potential oxidation of the PUFAs
in the diet. These measurements did not indicate any
difference in food intake in the two marine oil diet
groups in comparison to the control group. No signifi-
cant differences in liver weight or liver weight/body
weight ratio between the groups were detected, although
there was a trend towards a difference between the
groups (p = 0.074, Kruskal-Wallis test) to higher liver
weight/body weight in the FO group (Table 2).Table 1 Diet composition
Diet High fat
Energy%
Protein 20.7
Fat 46.0
Carbohydrate 33.3
Fat source (% in diet) Lard 21.3%
Soy oil 2.3%
Fatty acids (% of total fatty acids in diet)
Total SFA 42.9
Total MUFA 38.7
Total ω-6 PUFA 16.4
Total ω-3 PUFA 1.9
EPA 0.03
DHA 0.05
FO; fish oil, KO; Krill oil, SFA; saturated fatty acids, MUFA; monounsaturated fatty acPlasma lipids and fatty acid composition
Total plasma cholesterol was significantly decreased
by FO supplementation compared to the HF group
(Table 3). This was due to significant decreases in both
esterified and free cholesterol. Plasma TAG and PLs
were significantly decreased in the FO group whereas
non-esterified fatty acids (NEFA) were significantly de-
creased only in the KO group compared to HF. Notably,
the post hoc test did not detect any significant differ-
ences between the two marine oil groups in any of these
measurements.FO KO
20.6 20.7
46.2 45.9
33.2 33.3
Lard 15.7% Lard 15.6%
Soy oil 2.3% Soy oil 2.3%
Fish oil 5.8% Krill oil 5.7%
34.1 39.7
32.1 35.4
14.5 14.6
19.1 10.1
8.97 5.23
6.40 2.28
ids, PUFA; polyunsaturated fatty acids.
Table 2 Final body and liver weights
High fat FO KO K–W
Median (range) Median (range) Median (range) p
Final body weight (g) 33.7 (31.0–41.9) 32.1 (31.2–35.7) 36.2 (28.3–40.6) 0.097
Liver weight (g) 1.65 (1.43–1.84) 1.74 (1.52–1.76) 1.66 (1.24–1.99) 0.851
Liver weight/body weight (%) 4.5% (4.3–5.7) 5.1% (4.7–5.5) 4.5% (3.9–5.0) 0.074
Values are shown as median with the range in brackets. High fat (n = 9), FO (n = 5) and KO (n = 6). K-W, p indicates the p-value with the Kruskal-Wallace test.
FO; fish oil, KO; Krill oil.
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and TAG in the lipoprotein particles by size-exclusion
chromatography to investigate whether marine oil sup-
plementation changed the distribution of these lipids in
the various lipoprotein fractions (Table 4). FO signifi-
cantly lowered HDL and VLDL cholesterol while KO
had no significant effect compared to HF. FO also
strongly reduced VLDL cholesterol compared to the KO
group. TAG was only significantly decreased in the
VLDL fraction of the FO supplemented group. When
analyzed by size-exclusion chromatography, the VLDL
particles in FO fed mice eluted with the same retention
time as in the HF group, suggesting that no major
reduction in particle size had occurred (data not shown).
The fatty acid composition was analyzed only in total
plasma lipids due to limited amounts of sample. Quanti-
tative fatty acid analysis showed a decrease in total fatty
acids in both treatment groups with the difference being
statistically significant in the FO group (Table 5). The
decrease was due to decreased levels of total saturated
(SFA) and monounsaturated (MUFA) fatty acids and
omega-6 PUFAs but the amounts of omega-3 PUFAs
were significantly increased in both groups. The de-
creased levels of SFA, MUFA and omega-6 fatty acids
were due to decreased amounts of most fatty acid
species. Although these effects were less pronounced in
the KO group, KO significantly decreased arachidonic
acid (C20:4n-6) compared to HF. Instead, FO strongly de-
creased the amount of C18:2n-6. The amount of omega-3
PUFAs increased in plasma to the same extent in both
active treatment groups despite the markedly lower con-
tent of omega-3 PUFAs in KO. The relative abundanceTable 3 Plasma lipids
Plasma lipids High fat FO
mmol/L m
Total cholesterol 3.08 (2.82–3.28) 2.
Cholesterol esters 2.11 (1.88–2.32) 1.
Free cholesterol 0.96 (0.92–0.99) 0.
Triacylglycerol 1.12 (0.78–1.48) 0.
Phospholipids 3.56 (2.87–3.95) 2.
Nonesterified fatty acids 0.19 (0.14–0.29) 0.
Data is shown as median and range. High fat (n = 5), FO (n = 5) and KO (n = 6). a = H
p indicates the p-value with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil.of the omega-3 PUFAs (EPA >DHA> >DPA >ALA) mir-
rored the composition in the respective marine oil supple-
mented diets rather closely, indicating that the omega-3
PUFA composition is not changed during intestinal ab-
sorption. However, the composition in plasma from the
HF group was different with DHA being the dominating
omega-3 PUFA (DHA> > EPA ≈DPA ≈ALA). Similar but
less obvious trends were seen when comparing the relative
fatty acid composition (in wt %), see Additional file 3.
Liver lipids and fatty acid composition
The hepatic levels of total cholesterol, PLs and TAG, as
well as the fatty acid composition of the TAG and PL
fractions were analyzed. Total cholesterol was signifi-
cantly increased (≈25%) in both oil-supplemented groups
compared to HF (Table 6). Furthermore, total PLs were
significantly increased in the FO group, and also in the
KO group when analyzed as total fatty acid content
(see Tables 6 and 7). Total liver TAG content differed in
the study population (Kruskal Wallis p = 0.045), although
the post hoc test failed to identify significant differences
between the three groups, probably due to one individ-
ual with extremely high TAG levels in the HF group.
The extracted liver lipids were further separated by thin
layer chromatography and quantitative fatty acid analysis
of the TAG and PL fractions was performed, which
showed that FO significantly elevated total fatty acid
content in the TAG fraction compared to the HF group
(Table 8). This increase was due to increases in some
SFA species (specially palmitic acid (C16:0) and a >20-
fold increase in omega-3 PUFAs. KO did not signifi-
cantly affect total fatty acid amount, SFA, MUFA orKO K–W
mol/L mmol/L p
05 (2.00–2.46)a** 2.59 (2.07–3.42) 0.007
50 (1.36–1.80)a* 1.86 (1.27–2.44) 0.004
65 (0.50–0.66)a** 0.82 (0.68–0.98) 0.035
49 (0.26–0.68)a** 0.77 (0.46–1.00) 0.008
42 (2.17–2.52)a** 2.73 (2.27–3.26) 0.007
11 (0.02–0.14) 0.05 (0.00–0.18)b* 0.016
F vs. FO, b = HF vs. KO, *= p < 0.05, **= p <0.01 by Dunn’s test. K-W,
Table 4 Cholesterol and TAG content of the lipoprotein fractions in plasma
Cholesterol High fat FO KO K-W
mmol/L mmol/L mmol/L p
VLDL 0.11 (0.06–0.12) 0.04 (0.04–0.06)a*, c* 0.10 (0.07–0.12) 0.009
LDL 0.17 (0.14–0.61) 0.32 (0.27–0.37) 0.34 (0.17–0.51) 0.468
HDL 3.10 (2.42–3.36) 1.92 (1.71–2.21)a* 2.46 (1.85–3.15) 0.018
Triacylglycerol
VLDL 0.79 (0.42–0.92) 0.20 (0.11–0.30)a* 0.37 (0.32–0.50) 0.004
LDL 0.27 (0.23–0.39) 0.23 (0.09–0.32) 0.20 (0.08–0.25) 0.063
HDL 0.08 (0.04–0.19) 0.06 (0.03–0.13) 0.08 (0.07–0.22) 0.133
Data is shown as median and range. High fat (n = 5), FO (n = 5) and KO (n = 5). a = HF vs. FO, c = FO vs. KO, *= p <0.05 by Dunn’s test. K-W, p indicates the p-value
with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil, VLDL; very low density lipoprotein, LDL; low density lipoprotein, HDL; high density lipoprotein.
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content ≈ 8-fold. Notably, FO provoked a much stronger
increase (≈3-fold) in omega-3 PUFA content in liver
TAG compared to the effect of KO. In spite of the lower
incorporation of omega-3 PUFAs in TAG, KO was more
efficient in decreasing the amount of C20-C22 omega-6
fatty acids in this lipid fraction. Taken together these
changes resulted in significantly increased omega-3/omega-
6 ratios in both active treatment groups. For liver TAG fatty
acid composition as wt %, see Additional file 4.
Quantitative fatty acid analysis confirmed the in-
creased fatty acid content in liver PLs by FO and further
revealed a significantly increased fatty acid content in
the PL fraction also by KO. This was due to increases in
SFA, MUFA and omega-3 PUFAs in spite of decreased
omega-6 fatty acid species, especially C18:2 by FO and
C20:4 by KO and FO compared to HF (Table 7). The
increased amount of SFA (25-30%) was mainly due to
increases in C16:0 and C18:0. Interestingly, the EPA, DHA
and DPA contents were quite similar in the FO and KO
groups in spite of the lower omega-3 content in the KO
diet. For liver PL fatty acid composition given in wt %,
see Additional file 5.
Effect of marine oils on gene expression in the liver
Gene expression analysis was performed on genes cod-
ing for selected peroxisomal and mitochondrial proteins.
The expression of several genes involved in fatty acid
metabolism were upregulated in the FO group, e.g. genes
involved in uptake (Fatp-1) and β-oxidation of fatty acids
(Vlacs, Acox1, Ehhadh, Hsd17b4, Acaa1b, Decr2, Ech1
and Peci in peroxisomes and Cpt1a, Cpt1b, Hadha,
Acadvl, Acadm, Acads, Decr1 and Dci in mitochondria)
(Figure 2, see “Peroxisomal pathways” and “Mitochon-
drial pathways”) compared to HF. In line with the in-
creased expression of Acox1 mRNA, also peroxisomal
acyl-CoA oxidase (ACOX) activity was significantly in-
creased in the FO group. However, the increased mRNA
expression of the two Cpt1 genes did not translate into a
significant increase of total CPT1 activity in the FOgroup (Table 9). In addition, a number of genes encoding
enzymes that are involved in regulation of β-oxidation and
transport of metabolites were upregulated by FO, e.g. acyl-
CoA thioesterases (Acot6, Acot8 and Acot12 in peroxi-
somes and mitochondrial Acot2), as well as the short- and
medium-chain carnitine acyltransferases Crat and Crot.
Interestingly, KO decreased the expression of the mito-
chondrial-associated Acacb (acetyl-CoA carboxylase 2),
which produces malonyl-CoA, compared to FO (Figure 2,
“Mitochondrial pathways”). The decreased Acacb expres-
sion indicates a positive effect by KO on mitochondrial
β-oxidation rate by reduced production of the CPT1-
inhibitor malonyl-CoA.
Many of the genes that were upregulated by FO sup-
plementation are well known targets for PPARα and
involved in fatty acid degradation. Cytosolic acyl-CoA
thioesterase 1 (Acot1) is one of the most strongly PPARα-
regulated genes and a previously characterized target for
PPARα [39]. Acot1 expression was upregulated in the FO
group and also Hmgcs2 (mitochondrial rate limiting
enzyme in ketone body formation) was upregulated in
the FO group but not appreciably by KO (Figure 2, see
“Additional metabolic pathways” and “Mitochondrial path-
ways”), suggesting a more potent PPARα-activation by FO.
The expression of the first enzymes of the cholesterol/
isoprenoid synthesis pathway (Mvd, Mvk, Pmvk, Fdps
and Idi1) did differ in the total study set, but the post
hoc test only confirmed significant downregulation of
Mvd, Mvk and Hmgcr by KO compared to HF (Figure 2,
“Mevalonate pathway” and, “Additional metabolic path-
ways”), while no, or less pronounced decreases were
found with FO supplementation. Pcsk9, a well-known
regulator of degradation of the LDL receptor [40], was
significantly downregulated by both KO and FO. No
changes were found in the expression of lipoproteins
ApoB or ApoAII or the TAG-synthesizing enzyme Dgat2
by FO or KO. Fatty acid synthase (Fas) expression was
significantly downregulated by KO, in line with the (non-
significantly) lower activity of the enzyme (c.f. Table 9).
The increased FAS-activity in the FO group was however
Table 5 Total fatty acid composition of plasma lipids
Fatty acids High fat FO KO K-W
μg FA/ml plasma μg FA/ml plasma μg FA/ml plasma p
SFA 1255 (889–1928) 715 (570–731)a** 735 (611–925) 0.001
C10:0 0.9 (0.4–3.2) 1.0 (0.7–1.4) 1.8 (1.2–2.1) 0.126
C12:0 1.5 (0.6–2.9) 0.4 (0.3–0.6)a** 0.7 (0.5–1.0) 0.001
C14:0 15.3 (7.4–24.3) 5.8 (4.1–6.7)a** 11.4 (9.2–20.5) 0.003
C16:0 781 (524–1170) 422 (359–436)a** 482 (379–596) 0.002
C18:0 402 (311–637) 242 (181–271)a** 228 (187–274)b** 0.001
C20:0 11.0 (7.6–19.5) 4.6 (3.7–5.4)a*** 6.4 (5.1–8.1) 0.003
C22:0 16.2 (10.6–26.6) 9.7 (7.7–10.3) 13.1 (10.7–17.3) 0.199
C24:0 5.0 (2.8–8.4) 3.9 (3.0–4.2)a** 3.8 (3.8–4.8) 0.001
MUFA 679 (493–1115) 277 (217–292)a*** 351 (331–527) 0.001
C16:1n–9 11.7 (7.5–17.4) 4.4 (4.0–4.9)a** 5.7 (4.7–8.2) 0.001
C16:1n–7 45.2 (23.9–51.8) 18.9 (14.6–24.5)a**, c* 35.0 (24.7–53.0) 0.007
C18:1n–9 543 (397–919) 218 (170–232)a*** 254 (241–390) 0.000
C18:1n–7 42.5 (33.0–70.5) 20.1 (14.3–22.7)a** 36.9 (30.6–45.1) 0.004
C20:1n–9 12.9 (8.7–24.8) 3.7 (2.9–4.8)a*** 5.9 (4.6–7.6) 0.001
C20:1n–7 2.6 (1.7–4.2) 1.1 (0.8–1.4)a** 2.0 (1.8–2.5) 0.002
C22:1n–9 2.0 (1.3–4.1) 0.5 (0.4–0.6)a*, c** 3.0 (2.3–3.5) 0.004
C22:1n–7 1.4 (0.9–1.7) 0.6 (0.5–0.7)c*** 2.1 (1.8–2.6) 0.000
C24:1n–9 9.6 (6.5–14.3) 7.2 (6.3–7.8)a* 7.5 (6.0–10.2) 0.040
ω-6 PUFA 1490 (1080–2176) 468 (419–527)a*** 744 (513–815) 0.001
C18:2n–6 969 (677–1461) 283 (214–293)a*** 562 (351–615) 0.000
C18:3n–6 14.1 (8.2–22.8) 2.6 (2.3–3.0)a*** 4.8 (3.0–5.2) 0.001
C20:3n–6 48.4 (30.2–69.2) 12.8 (12.0–15.5)a** 15.0 (10.8–21.0)b* 0.001
C20:4n–6 455 (338–588) 189 (167–219) 136 (123–166)b*** 0.000
C22:4n–6 5.8 (4.2–10.3) 1.1 (0.8–1.1)a** 1.2 (1.0–1.4)b* 0.001
C22:5n–6 7.7 (4.3–12.0) 3.1 (2.5–3.8) 1.3 (1.1–1.6)b*** 0.000
ω–3 PUFA 272 (187–415) 773 (639–898)a** 696 (588–877)b** 0.001
C18:3n–3 18.3 (10.4–29.3) 3.8 (2.3–6.4)a** 11.3 (5.6–16.9) 0.002
C20:5n–3 21.4 (13.1–28.3) 420 (351–512)a** 400 (316–486)b* 0.001
C22:6n–3 212 (147–328) 261 (248–331)a* 268 (231–334)b* 0.013
C22:5n–3 14.1 (9.6–19.9) 31.2 (24.1–35.0)a** 26.0 (19.1–33.4)b* 0.002
ω-3/ω-6 PUFA 0.2 (0.2–0.2) 1.6 (1.5–1.7)a*** 1.1 (0.8–1.4) 0.000
Total FA 3712 (2679–5648) 2282 (1849–2427)a** 2406 (2175–3079) 0.002
Quantitative fatty acid composition of selected fatty acids in plasma. SFA; saturated fatty acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty
acids. Data are shown as median and range. High fat (n = 9), FO (n = 5), KO (=6). a = HF vs. FO, p <0.05, b = HF vs. KO, p <0.05, c = FO vs. KO, *= p <0.05,
**= p <0.01 and ***= p <0.001. K-W, p indicates the p-value with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil.
Table 6 Liver lipids
Liver lipids High fat FO KO K-W
μmol/g p
Total Cholesterol 5.6 (4.8–6.7) 6.9 (6.0–10.4)a* 7.0 (5.9–9.7)b* 0.005
Triacylglycerol 12.2 (8.0–50.8) 42.2 (22.7–55.4) 17.0 (6.7–32.7) 0.045
Phospholipids 18.5 (16.3–20.8) 21.7 (21.5–23.5)a** 20.7 (19.2–22.6) 0.002
Data is shown as median and range. High fat n = 9, FO n = 5, KO n = 6. a = HF vs. FO, b = HF vs. KO, *= p <0.05, **= p <0.01 for Dunn’s test. K-W, p indicates the
p-value with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil.
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Table 7 Fatty acid composition of the PL fraction in liver
Fatty acids High fat FO KO K-W
μg FA/g liver μg FA/g liver μg FA/g liver p
SFA 7174 (6094–8626) 9118 (8693–9471)a** 8918 (7882–9276)b* 0.001
C10:0 1.7 (0.9–3.8) 2.4 (1.3–2.7) 1.6 (0.6–3.0) 0.878
C12:0 1.8 (0.6–5.6) 4.7 (3.5–6.1)a* 2.5 (1.9–3.9) 0.022
C14:0 15.2 (10.1–17.4) 21.5 (19.5–23.3)a** 19.6 (17.4–27.4)b** 0.001
C16:0 3732 (3082–4211) 4990 (4560–5257)a* 5078 (4433–5170)b** 0.001
C18:0 2886 (2635–3975) 3816 (3682–4001)a** 3462 (3003–3650) 0.007
C20:0 72.3 (56.8–78.2) 72.4 (52.3–80.6) 85.8 (79.2–102)b** 0.005
C22:0 151 (130–169) 141 (98.4–142)c*** 188 (155–225) 0.001
C24:0 52.8 (34.4–75.1) 69.5 (61.4–77.5) 66.2 (55.7–74.3) 0.179
MUFA 1732 (1473–2232) 2008 (1722–2546) 2168 (1996–2915)b* 0.012
C16:1n–9 25.6 (20.3–33.5) 28.6 (22.9–36.9) 31.0 (27.2–40.2) 0.063
C16:1n–7 94.7 (67.3–131) 141 (118–165)a* 169 (103–249)b** 0.003
C18:1n–9 1257 (1095–1638) 1506 (1231–1998) 1614 (1472–2162)b* 0.015
C18:1n–7 220 (174–295) 225 (211–260) 249 (217–276) 0.198
C20:1n–9 31.9 (27.0–50.6) 32.4 (32.2–37.6) 32.0 (30.8–45.2) 0.600
C20:1n–7 7.2 (5.6–10.5) 8.2 (6.7–9.3) 8.2 (7.2–13.3) 0.410
C22:1n–9 7.0 (5.5–8.5) 4.9 (4.8–6.6)a* 6.5 (5.4–7.0) 0.020
C22:1n–7 5.1 (3.8–6.5) 4.7 (3.4–4.9)c** 6.5 (5.5–9.2) 0.006
C24:1n–9 51.3 (40.6–77.3) 61.9 (57.1–63.9) 50.5 (44.4–78.0) 0.172
ω–6 PUFA 6206 (5254–7494) 3874 (3697–4144)a*** 4768 (4056–5520) 0.001
C18:2n–6 2881 (2305–3231) 1935 (1677–2052)a*, c** 2865 (2449–3607) 0.004
C18:3n–6 45.4 (24.0–56.9) 16.6 (13.7–19.6)a*** 24.6 (18.8–30.8) 0.001
C20:3n–6 286 (210–344) 163 (153–210)a** 174 (155–248)b* 0.001
C20:4n–6 2984 (2470–3728) 1808 (1576–1818)a* 1629 (1324–1723)b*** 0.001
C22:4n–6 40.0 (31.8–60.4) 11.4 (9.3–12.0)a** 12.1 (10.1;13.7)b* 0.001
C22:5n–6 35.8 (27.2–67.8) 29.7 (27.1–35.2) 10.4 (9.6–11.6)b*** 0.001
ω-3 PUFA 1931 (1824–2155) 6189 (5560–6985)a*** 5660 (4417–6124)b* 0.001
C18:3n–3 18.4 (14.0–22.8) 19.2 (14.9–25.8)c 33.0 (27.6–39.8)b** 0.002
C20:5n–3 77.9 (52.0–83.8) 2057 (1621–2186)a*** 1435 (1211–2261)b* 0.001
C22:6n–3 1774 (1666–1970) 3615 (3308–4480)a** 3612 (2614–3964)b** 0.001
C22:5n–3 74.7 (59.3–95.7) 321 (296–371)a*** 276 (203–323)b* 0.001
ω–3/ω–6 PUFA 0.3 (0.3–0.4) 1.7 (1.3–1.7)a*** 1.1 (0.9–1.3)b* 0.001
Total FA 17281 (15088–20534) 21171 (20619–22608)a* 21626 (18584–22927)b** 0.001
Quantitative fatty acid analysis of the most abundant fatty acids in the PL fraction from liver. SFA; saturated fatty acids, MUFA; monounsaturated fatty acids, PUFA;
polyunsaturated fatty acids. Data are shown as median and range. High fat (n = 9), FO (n = 5), KO (n = 6). a = HF vs. FO, b = HF vs. KO, c = FO vs KO. *= p <0.05,
**= p <0.01 and ***= p <0.001. K-W, p indicates the p-value with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil.
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expression (see Table 9 and Figure 2, “Additional meta-
bolic pathways”).
No major changes in the expression of genes coding
for proteins in the citric acid cycle (Figure 2, “Mitochon-
drial pathways”), or oxidative phosphorylation (data not
shown) were observed in either group compared to the
HF group. However, Pdk4, a known PPARα responding
gene, was strongly upregulated in the FO group but notin the KO group (Figure 2, “Mitochondrial pathways”).
Soluble phosphoenolpyruvate carboxykinase 1 (Pck1) ex-
pression was increased in the FO group compared to the
KO group, but not when compared to HF (Figure 2,
“Additional metabolic pathways). The same pattern was
seen for the expression of the mitochondrial gluconeo-
genic gene Pck2, as well as the citric acid synthase cod-
ing gene Cs (Figure 2, “Mitochondrial pathways”). No
major changes were seen in the expression of selected
Table 8 Fatty acid composition of the TAG fraction in liver
Fatty acids High fat FO KO K-W
μg FA/g liver μg FA/g liver μg FA/g liver p
SFA 2567 (1678–12724) 9625 (5443–13484) 3741 (1279–7260) 0.036
C10:0 1.9 (1.3–7.3) 8.0 (4.9–11.0)a* 3.1 (1.4–8.1) 0.019
C12:0 7.9 (2.0–59.8) 37.2 (28.2–43.0)a* 14.0 (7.2–26.3) 0.016
C14:0 41.3 (27.3–240) 161.1 (122–270) 82.6 (21.9–167) 0.063
C16:0 2067 (1367–11132) 8642 (4733–12151)a* 3196 (1041–6389) 0.029
C18:0 294 (182–823) 610 (360–815) 251 (136–372)b* 0.026
C20:0 89.3 (32.1–166) 115.0 (60.7–132) 58.7 (31.3–97.0) 0.158
C22:0 17.8 (5.9–30.6) 18.5 (11.8–21.1) 13.0 (7.2–21.6) 0.567
C24:0 3.9 (1.5–5.6) 6.9 (4.4–8.0)c** 3.0 (1.7–3.7) 0.006
MUFA 3659 (2367–19647) 12583 (5295–18215) 4388 (1458–11092) 0.095
C16:1n–9 69.8 (42.6–487) 264.0 (116–442) 94.3 (24.5–303) 0.145
C16:1n–7 113 (77–1190) 771 (475–1202) 360 (48.4–1058) 0.075
C18:1n–9 3088 (2016–16228) 10246 (4347–15384) 3595 (1252–8971) 0.095
C18:1n–7 171 (108–1160) 540 (221–694) 200 (72.3–459) 0.148
C20:1n–9 135 (64.9–362) 181 (75.9–319) 68.9 (31.2–158) 0.080
C20:1n–7 26.7 (12.8–98.0) 49.3 (20.2–72.4) 20.3 (8.3–44.4) 0.116
C22:1n–9 26.9 (12.2–48.6) 24.1 (12.6–40.6) 17.2 (7.2–29.6) 0.160
C22:1n–7 5.7 (2.3–12.5) 6.7 (3.7–8.9) 5.3 (2.1–9.2) 0.621
C24:1n–9 2.8 (1.3–3.2) 3.6 (2.5–5.3)c* 2.0 (1.1–2.2) 0.020
ω–6 PUFA 1751 (1290–7085) 2611 (1684–3193) 1851 (822–2969) 0.507
C18:2n–6 1418 (1029–5911) 2262 (1442–2781) 1677 (744–2724) 0.516
C18:3n–6 35.7 (28.5–105) 29.2 (16.2–40.0) 24.2 (10.5–36.7) 0.053
C20:3n–6 77.2 (42.0–222) 61.0 (32.9–83.2) 30.0 (15.0–51.9)b** 0.006
C20:4n–6 121 (99.2–542) 133 (111–165)c* 60.9 (28.4–88.5)b** 0.002
C22:4n–6 37.7 (27.4–137) 39.7 (24.8–48.3)c* 13.6 (7.8–19.0)b** 0.002
C22:5n–6 23.8 (15.6–56.4) 47.1 (35.4–56.3)c*** 11.8 (6.2–17.0)b* 0.026
ω–3 PUFA 278 (210–1393) 6355 (4656–7148)a*** 2192 (831–3543) 0.000
C18:3n–3 55.9 (34.6–291) 190 (129–197) 146 (41.2–265) 0.135
C20:5n–3 11.9 (9.8–113) 1329 (1170–2156)a*** 594 (143–1048)b* 0.000
C22:6n–3 158 (127–688) 3097 (2200–3535)a*** 1004 (496–1542) 0.000
C22:5n–3 41.0 (25.9–217) 1275 (814–1486)a*** 330 (117–463) 0.001
ω–3/ω–6 PUFA 0.2 (0.2–0.2) 2.6 (2.0–2.8)a*** 1.2 (0.9–1.5)b* 0.000
Total FA 8274 (5559–40955) 30744 (17101–41288)a* 12380 (4398–24899) 0.029
Quantitative fatty acid analysis of the most abundant fatty acids in the TAG fraction from liver. SFA; saturated fatty acids, MUFA; monounsaturated fatty acids,
PUFA; polyunsaturated fatty acids. Data are shown as median and range. High fat (n = 9), FO (n = 5), KO (=6). a = HF vs. FO, b = HF vs. KO, c = FO vs. KO.
*= p <0.05, **= p <0.01 and ***= p <0.001. K-W, p indicates the p-value with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil.
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http://www.nutritionandmetabolism.com/content/11/1/20genes coding for proteins involved in apoptosis or in the
metabolism of reactive oxygen species, except for in-
creased expression of the pro-apoptotic Bid and uncoup-
ling protein 2 (Ucp2) (see “Mitochondrial pathway”), a
well-known PPARα target gene [41], and an increased
expression of epoxide hydrolase (Ephx2, see “Peroxi-
somal pathways”) by FO compared to KO.
Expression was also investigated for members of the
PPAR family of nuclear receptors, that are known tobind lipids as ligands and thereby respond to changes in
lipid homeostasis, and the PPARγ coactivators 1a and
1b. However, no significant differences in the expression of
these selected genes were found due to large variation of
expression levels between individuals (Figure 2, “Nuclear
transcription factors”). Although many PPARα regulated
genes were upregulated in the FO group, Pparα itself was
not significantly increased by FO or KO (p = 0.15 by
Kruskal-Wallis test). Ppargc1a showed a trend (p = 0.058
0 2 4 6 8 12 16 20 30 40
Mdh2
Pcx
Pck2
Pdk1
Pdk2
Pdk4
Pdp2
Pdha1
Cs
Ogdh
Aco2
Suclg2
Pgs1
Ucp2
Fatp-1
Cpt1a
Cpt1b
Cpt2
Acadvl
Acadl
Acadm
Acads
Hadha
Decr1
Dci
Acot2
Hmgcs2
Gpam
Acacb
Tomm20
Bid
HF
FO
KO
K-W
*
*
*
#
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
0 5 10 15 60 90 120150
Epxh2(tot)
Mlycd(tot)
Pex11
Acot4
Acot6
Acot8
Acot12
Crot
Crat(tot)
Aldh3a2(tot)
Peci
Ech1
Decr2
Scp2
Acaa1b
Acaa1a
Hsd17b4
Ehhadh
Acox1
Vlacs
Abcd3
Abcd2
Abcd1
HF
FO
KO
K-W
*
*
#
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
#
*
*
*
*
*
*
*
#
*
*
*
*
*
*
*
*
*
*
0 1 2 3 4 5
Idi1
Fdps
Pmvk
Mvk
Mvd
HF
FO
KO
K-W
*
* *
*
*
*
*
0 2 4 6
Acot1
Pck1
Pklr
Scd1
Acaca
Fas
Hmgcr
Ldlr
Pcsk9
Dgat2
Apoa2
Apob
Srebp1c
HF
FO
KO K-W
*
*
*
*
*
*
*
*
#
*
*
0 1 2 3 4
Ppara
Ppard
Pparg
Ppargc1a
Ppargc1b
HF
FO
KO
Figure 2 (See legend on next page.)
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Figure 2 Gene expression in liver. The graphs showing the relative mRNA expression of genes coding for selected proteins in “Peroxisomal
pathways”, “Mitochondrial pathways”, “Mevalonate pathway” and “Nuclear transcription factors” are generated from the TLDA array described
in Materials and Methods. The bars show the median and range of the relative expression in the control group (HF, dark grey bars), the FO
group (FO, light grey bars) and the KO group (KO, medium gray bars). Values are shown in relation to the expression of respective gene in one
individual of the HF group (n = 4 per group). The graph showing “Additional metabolic pathways” was generated by real time PCR on selected
genes as described in Material and Methods with the bars showing the median and the range of the relative mRNA expression in relation to
one individual (set to 1) in the HF group. HF; dark grey bars (n = 6), FO; light grey bars (n = 5) KO; medium grey bars (n = 6). Significance by
the Kruskal-Wallis test is shown to the right in each graph (K-W), and a star close to the bars show significance by the Dunn post hoc analysis
(* = p < 0.05, # = p < 0.01 for the post hoc test).
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Expression of Srebp1c (sterol regulatory element binding
protein-1c), which is a regulator of e.g. Fas and Acaca, was
also investigated, however, contradictory to expectation no
downregulation of the gene by KO was found (Figure 2,
“Additional metabolic pathways”).
Effect of marine oils on gene expression in small intestine
mRNA expression was investigated in the intestinal epi-
thelium and the expression data are presented relative to
the expression in the first segment of the small intestine
to visualize both changes in expression and the expression
pattern throughout the intestine. Gene expression of all
fatty acid handling proteins investigated, Cd36, I-Fabp,
and L-Fabp were significantly upregulated in all four seg-
ments of the small intestine, except for Cd36 in segment 4
in FO supplemented mice (Figure 3). This observation is
in line with the significant increase in Acot1 that indicates
that PPARα activation occurs also in the intestine of FO
supplemented mice. However, none of these genes were
significantly increased in the KO group. KO did not
change the expression of any of the studied genes
compared to HF except for a significant decrease in the
expression of Mttp in the first segment of the intestine.
However there were some significant differences seen
between the FO and KO groups in that the proximal
intestinal expression of Dgat1 and the distal intestinal
expression of Acat2 were higher in the FO group. The
expression of Apob and Dgat2 was not significantly chan-
ged by either FO or KO. No changes in the expression of
the cholesterol transporter Npc1l1, the efflux transporter
Abcg5 or the facilitated glucose transporter Slc2a2 (Glut2)
could be detected (data not shown).Table 9 Liver enzyme activities
Diet CPT1 activity CPT1 activity
nmol/mg/min - 15μM Malonyl-CoA nmol/mg/min +
High fat 2.35 (1.83–3.74) 1.24 (1.05–4.41)
FO 3.42 (2.22–3.73) 2.10 (1.61–2.20)
KO 2.50 (1.84–3.08) 1.49 (1.28–2.15)
p (K-W) 0.337 0.120
Acyl-CoA oxidase (ACOX), fatty acid synthase (FAS) and carnitine palmitoyltransfera
CPT1 activity was measured with and without the addition of 15 μM malonyl-CoA.
a = HF vs FO, c = FO vs KO. **= p <0.01 and ***= p <0.001. K-W, p indicates the p -valDiscussion
Omega-3 PUFA supplementation and adequate intake of
dietary omega-3 PUFAs is stated to have numerous
beneficial health promoting effects including TAG low-
ering in plasma in humans, which have also been found
in numerous animal studies [23]. The main outcome
was the demonstration of a different metabolic regula-
tion by KO and FO. FO significantly decreased several
plasma lipid parameters (TAG, PLs and cholesterol)
compared to HF, which was associated with lipid accu-
mulation in liver. However, the post hoc test did not
demonstrate any significant changes in total plasma
TAG, PL or cholesterol in the KO supplemented group
compared to HF, while plasma NEFA was significantly
reduced. In addition, there were no significant differ-
ences between the two marine oil groups except for
significantly lower VLDL cholesterol content in the FO
group.
FO and KO differently regulated expression of genes
involved in lipid degradation and synthesis. While FO
provoked a strong PPARα activation like response in
liver and intestine, these effects were weak, or absent, in
the KO group, which instead mainly decreased the
expression of genes involved in cholesterol and fatty acid
synthesis.
The major factors contributing to these differences are
likely the different content and structure of the omega-3
PUFAs in FO and KO. In this study we intentionally
supplemented the high fat diet with equal amounts of
oil (6% w/w) to compare the effects of commercially
available omega-3 supplements. Although the omega-3
content is about double in FO, the concentration of
omega-3 PUFAs in plasma was very similar between theACOX activity FAS activity
15μM Malonyl-CoA nmol/mg/min nmol/mg/min
16.8 (14.4–30.6) 0.31 (0.24–0.38)
43.8 (33.3–54.7)a** 0.57 (0.36–0.63)c***
22.4 (16.8–39.4) 0.20 (0.12–0.22)
0.005 0.001
se 1 (CPT1) activities were measured as described in Materials and Methods.
Data shown as median and range. High fat (n = 6), FO (n = 5) and KO (n = 6).
ue with the Kruskal-Wallace test. FO; fish oil, KO; Krill oil.
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Figure 3 Gene expression in small intestine. mRNA expression of genes coding for proteins in fatty acid uptake and lipid synthesis in the
intestinal epithelium of the four segments relative to the expression in segment 1 (S1) of one individual in the HF group. Graphs show the median
expression value and range of each group. HF; dark grey bars (n = 6), FO; light grey bars (n = 5) KO; medium grey bars (n = 6). a(segment) = HF vs. FO,
p < 0.05; b(segment) = HF vs. KO, p < 0.05; c(segment) = FO vs. KO, **p < 0.01 for Dunn post hoc analysis after significant differences with the Kruskal-Wallis
test, marked as K-W over respective segment in the HF group.
Tillander et al. Nutrition & Metabolism 2014, 11:20 Page 13 of 17
http://www.nutritionandmetabolism.com/content/11/1/20two marine oil groups suggesting a higher bioavailability
of KO, or that the content of omega-3 PUFAs in KO in
our study is enough to obtain maximal plasma concen-
trations of omega-3 fatty acids. Incorporation of omega-
3 PUFAs in PLs has been suggested to give these lipids a
higher bioavailability [14,42,43], in fact, PLs enriched
from KO was shown to be even more efficient in lower-
ing plasma cholesterol than KO itself when given to rats
fed a high cholesterol diet [44].
Unfortunately, in the present study was not enough
plasma to analyze the fatty acid composition in TAG
and PLs separately so it is not clear whether the similar
levels of omega-3 PUFAs measured in plasma of the
two groups are due to a specific enrichment in the PL
fraction of the KO feed mice, which may be the case.
However, the ratio of EPA/DHA (EPA > DHA) in total
plasma was very similar in the FO and KO groups and
rather closely resembled the ratio in the diet, indicating
that these fatty acids are not modified during uptake in
the intestine and transport in plasma. It is however
evident that the omega-3 fatty acids are redistributed
between the TAG and PL fractions following uptake and
incorporation into liver lipids and that EPA is further
metabolized to DHA, thereby markedly increasing the
DHA/EPA ratio. DHA is mainly esterified into PLs in
liver of the HF mice (constituting >90% of the omega-3
fatty acids in this fraction) and surprisingly reaching
almost 50% of the DHA levels in the FO and KO groups.
FO decreased total omega-6 fatty acids in total plasma
lipids and liver PLs, while KO mainly lowered longer
chain omega-6 fatty acid species in plasma and liver
PLs. Both treatments thereby significantly increased
the omega-3/omega-6 ratio in plasma compared to HF
alone. Since KO specifically lowered the arachidonic acid
content in the liver PL fraction and in plasma more
efficiently than FO, KO may have a more potent anti-
inflammatory effect. Such an effect by KO was seen in
another FO and KO comparing supplementation study
on rheumatoid arthritis with balanced amounts of DHA
and EPA [45]. The decreased arachidonic acid levels are
also likely to decrease the amounts of 2-arachidonoylgly-
cerol (2-AG), a potent signaling lipid, as previously
described [17]. Krill powder, which is also rich in omega-3
containing PLs, was shown to decrease another arachi-
donic acid derived endocannabinoid, anandamide (N-
arachidonoylethanolamide, AEA), and its related metaboli
tes palmitoylethanolamide (PEA) and oleoylethanolamide(OEA) in plasma of obese men [46]. KO has further been
shown to be protective in a rat model of inflammatory
bowel disease in which KO seemed to both act as an anti-
inflammatory as well as anti-oxidative agent in the colon
of these animals [31].
The plasma TAG lowering effect of EPA and DHA have
been proposed to be at least partly mediated via PPARα,
similar to fibrates, by stimulating the β-oxidation systems
that would drain the liver of fatty acids and thereby
decrease the production of VLDL particles. Our data,
however, show a 3-4 fold TAG accumulation in livers from
FO supplemented mice in spite of an apparent PPARα
activation in both liver and intestine. Similar, but less pro-
nounced, changes were seen also for fatty acids in plasma
and liver PLs. The apparent ‘transfer’ of PLs from plasma
to liver may reflect increased membrane synthesis, e.g.
proliferation of peroxisomes (at least for the FO group) as
indicated by increased expression of peroxisomal enzymes
and mitochondria as indicated by slightly increased citrate
synthase expression (see Figure 2). Another possibility is
that liver PLs increase as a result of decreased HDL pro-
duction that may at least in part explain the decrease in
plasma HDL. Since fatty acid composition and amounts
are similar in plasma and liver PLs in FO and KO supple-
mented mice, it is likely that the stronger PPARα activa-
tion seen in liver and intestine is mediated via omega-3
PUFAs of the TAG fraction of FO supplemented mice.
The increase in the fatty acid content of liver TAG
found in the FO group indicates that the observed up-
regulation of genes coding for catabolic pathways (e.g.
the upregulation of genes coding for fatty acid oxidation
and the increased ACOX activity and possibly elevated
activity of CPT1) is apparently of minor importance in
determining liver lipid levels in these animals. It should
be noted that PPARα activation by e.g. fenofibrate also
increases liver expression of lipogenic genes a with con-
comitant increase in fatty acid synthesis and TAG accu-
mulation [47]. Thus, our data are consistent with PPARα
activation by FO, although weaker than fibrate treat-
ment, and hence increased lipid synthesis and possibly
decreased VLDL secretion may at least partially explain
the observed TAG accumulation in liver. Also, a recent
study demonstrated that DHA attenuates postprandial
hyperlipidemia in a PPARα dependent manner by activa-
tion of fatty acid oxidation genes in the intestine leading
to decreased TAG and apoB secretion. However, PPARα-
independent pathways that reduce the assembly and
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[23,48]. Some data indicate that FO decreases VLDL pro-
duction mainly due to decreased plasma NEFA, which is
suggested to be the main source of fatty acids for VLDL
synthesis [23]. However only KO significantly decreased
fasting plasma NEFA in our study but did not significantly
change plasma TAG, suggesting additional mechanisms
being involved. EPA is reported to inhibit DGAT activity
in liver [49,50], and also negatively influence the assembly
and secretion of VLDL via incorporation into choline and
ethanolamine PLs, which due to the higher total content
of EPA in FO could be an additional possible explanation
for the different effects on plasma TAG by FO and KO in
our study [51]. This may also explain why similar levels of
omega-3 PUFAs were found in plasma, since the TAG
pool entering the VLDL fraction might be affected by the
high levels of EPA, and that EPA may be shunted into the
cytosolic TAG-pool for storage rather than entering VLDL
in the FO group, while the PL pool (which contained simi-
lar amounts of omega-3 PUFAs in both groups in liver)
that enters the different lipoprotein fractions, e.g. HDL,
may not be as affected [51]. We did not assess the severity
of the lipid accumulation in liver in this study and there-
fore we can not predict the health effects associated with
these changes and effects of long-term feeding of these
omega-3 supplements.
KO feeding reduced the expression and the activity of
fatty acid synthase (Fas), which is in line with previous
findings that KO supplementation decreases the mRNA
expression of this protein more efficiently than FO
[25,27,28]. Expression of Acacb (acetyl-CoA carboxylase
2) was also decreased in the KO group compared to the
FO group, which rather showed an increased expression
of this gene. Acetyl-CoA carboxylase 2 is associated with
mitochondria and generates malonyl-CoA, which is a key
regulator of energy homeostasis [52], and deletion of
Acacb in mice promotes fatty acid oxidation and increased
energy expenditure [53,54]. Therefore, in conjunction with
an apparent downregulation of Fas (and possibly Acaca)
and thereby fatty acid synthesis in the KO group, this may
provide a possible alternative mechanism by which KO
maintains lower liver TAG levels compared to FO.
KO also reduced the mRNA expression of the first
segments of the cholesterol/isoprenoid synthesis path-
way, including the rate-limiting enzyme in cholesterol
synthesis HMG-CoA reductase. However, the reduction
in expression seen in our current study did not reflect in
significant changes in plasma cholesterol (-16%), and
liver cholesterol was even slightly increased as in the FO
group. This was also seen in a low fat/omega-3 PUFA
balanced fish and krill oil based study in which KO
caused a similar downregulation in expression of genes
involved in gluconeogenesis and cholesterol and fatty
acid synthesis without changing plasma lipids [24].Similar amounts of KO supplementation have previously
been shown to decrease plasma and liver cholesterol in
C56BL/6 mice on a HF diet, however in this study the
mice were fed a different high fat diet containing butter-
milk and 0.15% cholesterol ± KO for 8 weeks which may
explain the different results [26]. More experiments are
needed to elucidate the discrepancy between gene ex-
pression and plasma/liver cholesterol levels, e.g. meas-
urement of total body cholesterol pool and bile acid and
cholesterol synthesis and excretion.
In the present study we have also investigated the
effects of FO and KO on gene expression of proteins
involved in lipid metabolism in the small intestine. A
similar trend in gene regulation as in the liver could be
seen in the intestine of these animals. The expression of
genes involved in fatty acid modulation and transport,
such as Acot1, Cd36, I-fabp and L-fabp were all upregu-
lated by the FO-containing diet, which is in line with
previous findings of PPARα activation in the intestine
during increased ligand availability [55]. KO on the other
hand did not promote the same response to these
PPARα driven genes. The increased expression of fatty
acid transporters in the intestine of the FO fed group
would potentially lead to an enhanced chylomicron pro-
duction due to increased uptake of fatty acids, however
FO has previously been shown to cause PPARα activa-
tion and thereby increased β-oxidation in murine intes-
tine [56], which may balance an increased uptake of
fatty acids. In a recent study, fenofibrate was shown to
reduce blood TAG content in the postprandial state in
part due to decreased dietary fat absorption and in-
creased β-oxidation of fatty acids in spite of upregulation
of chylomicron synthesizing genes and fatty acid trans-
porters [57]. It is possible that the different effects of FO
and KO may in part be due to differences in PPARα acti-
vation and thereby oxidative degradation of fatty acids in
the small intestine, although the quantitative importance
of fatty acid oxidation in the intestine is likely to be
small. The only significant changes found in the KO
group in genes coding for proteins in the chylomicron
synthesis pathway was a downregulation of Mttp in the
first intestinal segment by KO compared to HF diet,
and a significant difference between FO and KO in the
expression of Acat2 (in segment 3) and Dgat1 (in seg-
ments 2 and 3). Feces were not collected for absorption
studies or lipid analysis in our study, therefore it is not
clear whether omega-3 PUFAs per se, or omega-3
PUFAs in TAG versus PLs, affect dietary lipid absorp-
tion in the small intestine. Some data indicate that FO
may reduce lipid uptake in the intestine, or at least
delay efflux into the circulation by a transient accumu-
lation of lipids in the enterocytes [58]. Whether KO
affects lipid uptake in the intestine remains to be
studied.
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Both FO and KO raised plasma levels of omega-3 PUFAs
to the same extent in spite of a markedly lower omega-3
PUFA content in the KO diet. FO lowered plasma TAG,
PL and cholesterol and KO lowered NEFA in compari-
son to the control group. The two omega-3 fatty acid
supplementations also promoted different gene expres-
sion profiles in liver and intestine with FO causing an
apparent PPARα response by increasing the expression
of genes coding for proteins in the two β-oxidation sys-
tems and other lipid metabolizing genes. In contrast, KO
supplementation rather acted as a negative regulator of
endogenous cholesterol and fatty acid synthesis, at least
at the mRNA level. The stronger plasma lipid lowering
effect with FO can be partly explained by increased lipid
accumulation, mainly as TAG, in liver in spite of increased
PPARα activation that may not compensate for decreased
VLDL secretion. The physiological/pathological implica-
tions of the liver lipid accumulation by FO are not clear
and may depend on diet composition and dose of FO and
should be evaluated.Additional files
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